Patient Advocacy sessions were again an integral part of EHA’s annual congress program! PDFs of all three patient advocacy sessions are now available. Click on the respective presentation to download the slides.
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the European Hematology Association that took place in Vienna in June 2014.
Where is your patient group? Where do you want to get to? How you will get there? Patient organisations usually find several issues when trying to achieve their objectives due to limitations in terms of resources, time or strategy. However, some other are able so overcome these barriers and succeed in their mission. So how are they able to make it? The answer is simple: they have a plan. Continue reading
Myeloma Patients Europe will hold an online webinar on smoldering myeloma and the latest updates in its field of research. The talk will be given by Dr Jens Hillengaß, Haematology and Oncology Deparmtment at the University of Heidelberg (Germany) and Dr Maria Victoria Mateos, Haematology Department at the University Hospital of Salamanca (Spain) Continue reading
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology that took place in San Francisco in December 2014. Continue reading
Myeloma Patients Europe will be present at the 56th American Society of Hematology Annual Meeting, to be held in San Francisco betweeb 6 and 9 December.
Over 20.000 people from all arround the globe will attend the largest hematology event in the world. Hundreds of sessions, posters and exhibits will bring together, not only hematologists, but also other stakeholders, such as non-clinical researchers, nurses, industry and, of course, patients. Continue reading
The Oncologic Drugs Advisory Committee (ODAC), a board of the US Food and Drug Administration (FDA), voted 5 to 2 against the approval recommendation of panobinostat in combination with bortezomib and dexamethasone in multiple myeloma patients who have received at least one prior therapy. Continue reading
Myeloma Patients Europe is currently developing a European Atlas of Access to Myeloma Treatment.
Access to treatment across Europe is extremely variable. Patient group advocacy can make a huge difference in improving access, but often doesn’t have the evidence, knowledge and tools to advocate effectively. Continue reading
Authors: Heinz Ludwig, Pieter Sonneveld, Faith Davies, Joan Bladé, Mario Boccadoro, Michele Cavo, Gareth Morgan, Javier de la Rubia, Michel Delforge, Meletios Dimopoulos, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Philippe Moreau, Hareth Nahi, Torben Plesner, Jesús San-Miguel, Roman Hajek, Pia Sondergeld and Antonio Palumbo.
The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions,the prolongationof remission duration,and extended survival becoming realistic goals, with a cure being possible in a small but growing numberof patients. Continue reading
For yet another year, Myeloma Patients Europe will be present at the European Society for Medical Oncology Congress. The event will take place in Madrid between the 26 to 30 of September.
The main congress of European Oncology is expected to meet over 16.000 attendees from over 120 countries. ESMO 2014 intends to merge state-of-the-art oncology with the latest breakthrough discoveries, from cost-effective anti-cancer treatments to best supportive care. Continue reading